Background: For newly diagnosed chronic myeloid leukemia (CML) patients, early access to tyrosine kinase inhibitors (TKIs) is a consistent predictor of adherence and optimal response. The expense of targeted therapies, however, may result in high out-of-pocket costs for initiating therapy that could be a barrier to starting treatment.

Objective: To examine the association between TKI out-of-pocket costs, initiation, and health care utilization and costs among patients who initiated TKI within 12 months after initial CML diagnosis.

Methods: Individuals aged 18-64 years with an initial diagnosis of CML were identified in the IBM MarketScan Commercial Database between April 11, 2011, and December 31, 2014. The association between cost sharing and TKI initiation was evaluated using a multivariable logistic regression model applied to patients receiving therapy within a month of diagnosis and within 1-12 months after diagnosis. Health care utilization was compared using negative binomial regression models. Health care cost differences between the 2 patient groups were estimated using generalized linear models. All models were controlled for potential confounding factors.

Results: The study sample consisted of 477 patients, with 397 (83.2%) patients initiating TKI within the first month of CML diagnosis and 80 (16.8%) after the first month. Out-of-pocket costs for the initial 30-day supply of TKI medications were not found to be a significant predictor of TKI initiation time. Patients initiating therapy within a month were less likely to have all-cause hospitalizations (IRR = 0.35; = 0.02) or CML-specific hospitalizations (IRR = 0.27; < 0.01). Over the 12-month follow-up period, they incurred $9,923 more in TKI pharmacy costs ( < 0.05), but patients initiating therapy after the first month of diagnosis incurred $7,582 more in medical costs, $218 more in non-TKI pharmacy costs, and $2,680 more in total health care costs ( > 0.05).

Conclusions: Patients with TKI initiation within the first month of diagnosis had higher TKI pharmacy costs that were partially offset by lower medical and non-TKI pharmacy costs, resulting in lower overall total health care costs. Findings suggest that earlier TKI initiation may reduce the risks of hospitalizations, which could result in potential medical cost savings in the first 12 months of treatment.

Disclosures: No outside funding supported this study. The authors have no relationships or financial interests to report with any entity that would pose a conflict of interest with the subject matter of this article. A poster presentation of the study was made at the 11th American Association for Cancer Research (AACR) Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, on November 2-5, 2018, in New Orleans, LA.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397890PMC
http://dx.doi.org/10.18553/jmcp.2019.25.10.1140DOI Listing

Publication Analysis

Top Keywords

health care
24
tki initiation
16
pharmacy costs
16
care utilization
12
out-of-pocket costs
12
initiating therapy
12
therapy month
12
month diagnosis
12
patients initiating
12
costs
11

Similar Publications

Aim: The purpose of this study is to compare the efficacy of an artificial intelligence (AI)-based care plan learning strategy with standard training techniques in order to determine how it affects nursing students' learning results in newborn resuscitation.

Methods: Seventy third-year nursing students from a state university in Türkiye participated in the study. They were split into two groups: the experimental group, which received care plans based on AI, and the control group, which received traditional instruction.

View Article and Find Full Text PDF

Intro: The article tests the hypothesis that we can draw practical knowledge from the experience of service providers operating in the past. The research questions were formulated: can the historical example of the organization of medical care in the Polish Children's Hospital named after Karol and Maria be used as a viable example today? Is it relevant for contemporary practitioners? And do we still use the knowledge of predecessors? The authors decided to use the interwar Hospital and an operating paediatric ward of the Child-Friendly Hospital for a comparative analysis.

Methods: The model of the European Regional Office of the World Health Organization for integrated delivery of health services was adopted as the analysis framework.

View Article and Find Full Text PDF

Introduction: The sense of smell is one of the most developed and important senses that forms the bond between the newborn and the mother and allows the newborn to reach the mother's breast. The sense of smell begins to form during intrauterine life, and the sense of smell can be a marking tool for a newborn baby, so that the baby can recognize both his mother and his immediate environment and develop his behaviour accordingly. This is necessary not only for feeding babies but also for them to feel safe and peaceful in their new environment.

View Article and Find Full Text PDF

Reassurance for Patients-Essential Not Optional.

J Eval Clin Pract

February 2025

Initiative for Slow Medicine, Berkeley, California, USA.

Appropriate patient reassurance is an essential feature of clinical practice. My recent experience as a patient, interpreted via my expertise as a health services researcher, led me to insights on ideal and suboptimal reassurance styles in the context of worrisome symptoms. Reassurance is complex: often poorly defined in the scientific literature, rarely rigorously studied, imperfectly understood, and requiring some adaptation to each patient situation.

View Article and Find Full Text PDF

Introduction: Rheumatoid arthritis (RA) is a progressive autoimmune inflammatory disease. According to the European League Against Rheumatism (EULAR), the stages of RA progression include pre-RA, preclinical RA, inflammatory arthralgia, arthralgia with positive antibodies, arthralgia suspected of progressing to RA, undifferentiated arthritis and finally established RA. According to the Community Oriented Program for Control of Rheumatic Diseases (COPCORD), the prevalence of RA in Mexico is 1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!